Showing results (91-100 of 287) with videos related to

Sort By:
Pageof 29
Clinical Chemistry|August 8, 2022
An Update on Laboratory-Based Diagnostic Biomarkers for Multiple Sclerosis and BeyondRuba S Saadeh, Paola A Ramos, Alicia Algeciras-Schimnich, et al.
Multiple Sclerosis and Related Disorders|October 1, 2025
Neurofilament light chain levels differentiate ischemic from inflammatory optic neuropathiesShailee Shah, Sara Mariotto, Eoin P Flanagan, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 25, 2021
Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRIPietro Zara, Valentina Floris, Eoin P Flanagan, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|January 30, 2014
Successful endovascular repair of an unusual right-to-left shunt presenting with cerebral ischemiaNicholas L Zalewski, Elizabeth A Coon, Frank Cetta, et al.
The Neurologist|September 4, 2025
Does Initiation of Disease Modifying Therapy in Patients With Radiologically Isolated Syndrome Reduce their Risk of Conversion to Multiple Sclerosis? A Critically Appraised TopicAimen Vanood, Nicholas L Zalewski, Lisa A Marks, et al.
Brain Communications|July 13, 2022
Diagnosis of coexistent neurodegenerative dementias in multiple sclerosisDiana P Londoño, Kogulavadanan Arumaithurai, Eleni Constantopoulos, et al.
European Journal of Neurology|May 22, 2026
Long-Term Outcomes in Stiff Person Spectrum DisorderGeorgios Mangioris, Andrew McKeon, James H Bower, et al.
Mayo Clinic Proceedings|November 5, 2013
[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathyEoin P Flanagan, Christopher H Hunt, Val Lowe, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 20, 2020
Inflammatory activity following motor progression due to critical CNS demyelinating lesionsShreya Nayak, Elia Sechi, Eoin P Flanagan, et al.
Multiple Sclerosis and Related Disorders|February 15, 2022
Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum StudyEoin P Flanagan, Michael Levy, Eliezer Katz, et al.
Pageof 29